^
    Apply
    First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer (NCT05304962)
    Phase 1
    Regor Pharmaceuticals Inc.
    Recruiting
    Last update posted :
    10/13/2023
    Initiation :
    03/04/2022
    Primary completion :
    02/28/2024
    Completion :
    08/28/2024
    HER-2 • PIK3CA • CDK4
    |
    HER-2 negative • PIK3CA mutation
    |
    GDC-4198